The uncontrolled proliferation of malignant lymphoblasts is theIn contrast to the fast growing knowledge about the acti- pressing signals. One major candidate for growth arrest of nor-

genetics that flow-sorted CD34 + /CD38 − stem cell populations In three patients a mosaic of normal and abnormal metaphasesharbor clonal leukemia-specific cytogenetic abnormalities. 2,3,6 was found in the highly purified stem cell subpopulations. We Taken together, these data suggest that the leukemogenic gression-associated secondary genetic events likewise occur

B-cell chronic lymphocytic leukemia (B-CLL) is a slowly progressive disease characterized by the clonal expansion of CD5+/CD23+ B lymphocytes. The malignant transformation is assumed to occur at the level of mature B lymphocytes. We asked whether CD34+ progenitor cells are involved in the malignant process in B-CLL. Furthermore, we investigated the possibility of aberrant CD34 expression by the malignant B-cell clone. Bone marrow and peripheral blood samples from 75 patients with B-CLL were tested for the presence of trisomy 12 and deletion of the retinoblastoma gene (Rb) by fluorescence in situ hybridization. CD34+ subpopulations were isolated by fluorescence-activated cell sorting and analyzed for the presence of the informative genetic marker. Bone marrow and peripheral blood samples of 10 B-CLL patients were analyzed for coexpression of CD34/CD5/CD20. Trisomy 12 was detected in 15 of 75 (20%) and Rb-deletion was detected in 6 of 30 patients (20%). In 7 patients with trisomy 12, hematopoietic progenitor cells were sorted, with the sort purity being between 85% and 99.8%. The genetic marker was detected in the CD34+/CD38+ cells as well as in the CD34+/38− subsets in 3 patients. Progenitor cells were also sorted in 2 patients with Rb-deletion. In 1 patient, Rb-deletion was present in 10% of CD34+/38+ cells. In the other patient, Rb-deletion was neither detected in the CD34+/38+ nor in the CD34+/CD38− subsets. In all 10 patients investigated for coexpression of CD34/CD5/CD20, we could not find a subpopulation coexpressing these markers. We conclude that trisomy 12 and Rb-deletion are present in a considerable subset of patients with B-CLL. In part of these patients, the genetic marker was detected at the level of CD34+ stem cells. CD34 expression is not related to an aberrant phenotype of the malignant B-cell clone. These results suggest that the malignant transformation in B-CLL may involve early hematopoietic stem cells and place a note of caution on future strategies using autologous stem cell transplantation.

No abstract

Peritoneal exudate cells from mice injected with immunostimulatory agents were evaluated for their ability to promote hybridoma growth. Peritoneal cells from mice receiving peritoneal injections of either Freund's incomplete adjuvant or pristane, seven days prior to harvesting, produced the greatest number of antibody-producing hybridomas. Freund's incomplete adjuvant produced 16 fold more peritoneal cells than unstimulated mice, thus reducing the number of mice needed to supply feeder cells for the hybridoma cultures. In separate experiments a number of B-lymphocyte stimulating lectins and factors were tested for their ability to promote hybridoma growth. 2-mercaptoethanol (25 microM) routinely increased the number of antibody producing hybridomas by 5 to 15 fold. 2-mercaptoethanol had a varying ability to increase the numbers of hybridoma colonies. The cloning efficiency, rate of cell growth and antibody production of hybridoma cell lines, previously produced in the absence of 2-mercaptoethanol could also be increased when this reducing agent was added to the culture medium.